These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

692 related items for PubMed ID: 22042970

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
    Chen Y, Lisok A, Chatterjee S, Wharram B, Pullambhatla M, Wang Y, Sgouros G, Mease RC, Pomper MG.
    Bioconjug Chem; 2016 Jul 20; 27(7):1655-62. PubMed ID: 27270097
    [Abstract] [Full Text] [Related]

  • 3. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.
    Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP.
    Mol Imaging Biol; 2020 Feb 20; 22(1):190-197. PubMed ID: 31140110
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.
    Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, Kulkarni HR, Schuchardt C, Baum RP, Pienta KJ, Pomper MG, Ross AE, Gorin MA, Rowe SP.
    Mol Imaging Biol; 2020 Feb 20; 22(1):181-189. PubMed ID: 31115751
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand.
    Boschi S, Lee JT, Beykan S, Slavik R, Wei L, Spick C, Eberlein U, Buck AK, Lodi F, Cicoria G, Czernin J, Lassmann M, Fanti S, Herrmann K.
    Eur J Nucl Med Mol Imaging; 2016 Nov 20; 43(12):2122-2130. PubMed ID: 27329046
    [Abstract] [Full Text] [Related]

  • 9. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
    Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG.
    Mol Imaging Biol; 2015 Aug 20; 17(4):565-74. PubMed ID: 25896814
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.
    Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Ponnala S, Babich JW.
    Eur J Nucl Med Mol Imaging; 2017 Apr 20; 44(4):647-661. PubMed ID: 27847991
    [Abstract] [Full Text] [Related]

  • 11. Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP, Li X, Trock BJ, Werner RA, Frey S, DiGianvittorio M, Bleiler JK, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG.
    J Nucl Med; 2020 Feb 20; 61(2):183-188. PubMed ID: 31451492
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N, Kimura H, Onoe S, Watanabe H, Matsuoka D, Arimitsu K, Ono M, Saji H.
    J Nucl Med; 2016 Dec 20; 57(12):1978-1984. PubMed ID: 27417647
    [Abstract] [Full Text] [Related]

  • 14. Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [18F]DCFPyL PET Imaging.
    Roy J, White ME, Basuli F, Opina ACL, Wong K, Riba M, Ton AT, Zhang X, Jansson KH, Edmondson E, Butcher D, Lin FI, Choyke PL, Kelly K, Jagoda EM.
    Mol Imaging Biol; 2021 Oct 20; 23(5):745-755. PubMed ID: 33891265
    [Abstract] [Full Text] [Related]

  • 15. Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer.
    Jansen BHE, Yaqub M, Voortman J, Cysouw MCF, Windhorst AD, Schuit RC, Kramer GM, van den Eertwegh AJM, Schwarte LA, Hendrikse NH, Vis AN, van Moorselaar RJA, Hoekstra OS, Boellaard R, Oprea-Lager DE.
    J Nucl Med; 2019 Dec 20; 60(12):1730-1735. PubMed ID: 31000583
    [Abstract] [Full Text] [Related]

  • 16. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.
    Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M.
    J Nucl Med; 2018 Jul 20; 59(7):1076-1080. PubMed ID: 29269569
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging.
    Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Leotta K, Eder M, Neels OC, Haberkorn U, Giesel FL, Kopka K.
    J Nucl Med; 2017 Mar 20; 58(3):425-431. PubMed ID: 27789722
    [Abstract] [Full Text] [Related]

  • 20. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi.
    Gorin MA, Marashdeh W, Ross AE, Allaf ME, Pienta KJ, Pomper MG, Rowe SP.
    Nucl Med Commun; 2017 Sep 20; 38(9):795-798. PubMed ID: 28704341
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.